Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

{
  "signal_id": "ac895a53-323b-012f-3af7-309acf6985ea",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-07-08T10:30:00+00:00",
  "company": {
    "name": "Bio-Techne",
    "domain": "bio-techne.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/bio-techne-launches-expanded-rd-systems-ai-engineered-designer-protein-portfolio-302820164.html",
    "title": "Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio",
    "excerpt": "Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows MINNEAPOLIS , July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio , designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents. By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes. These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together...",
    "product": "R&D Systems AI-Engineered Designer Protein portfolio",
    "summary": "Bio-Techne Corporation has launched new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, aimed at improving reproducibility in cell therapy and advanced cell culture workflows.",
    "location": "Minneapolis, Minnesota, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS667889/Bio-Techne-Corporation-logo-Logo.jpg?id=OA2753909&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "R&D Systems AI-Engineered Designer Protein portfolio",
      "full_text": "R&D Systems™ AI-Engineered Designer Protein portfolio",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-07-08T10:30:00Z",
    "location_data": [
      {
        "city": "Minneapolis",
        "state": "Minnesota",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-07-08",
    "article_sentence": "Bio-Techne Corporation (NASDAQ: TECH ), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio , designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows."
  }
}

curl https://signals.autobound.ai/v1/signals/ac895a53-323b-012f-3af7-309acf6985ea \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bio-techne.com","limit":20}'